SCHEDULE: Janus Henderson Discloses 4.0% Stake in Entrada
Beneficial Ownership Report (Amendment)
Janus Henderson Group plc has filed an amended Schedule 13G, disclosing a 4.0% beneficial ownership stake in Entrada Therapeutics, Inc. as of June 30, 2025.
Summary
- Janus Henderson Group plc reported beneficial ownership of 1,521,281 shares of Entrada Therapeutics, Inc. common stock.
- This ownership represents 4.0% of the total class of securities.
- The shares are held with shared voting power and shared dispositive power.
- The filing is an Amendment No. 2 to a Schedule 13G, indicating a passive investment intent.
- The date of the event requiring this statement is listed as June 30, 2025.
Sentiment
Score: 5
Explanation: The filing is a neutral, factual disclosure of beneficial ownership and does not contain information that would inherently indicate positive or negative sentiment regarding the issuer's performance or prospects.
Positives
- NA
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- NA
Industry Context
Schedule 13G filings are routine disclosures by institutional investors who acquire a significant stake in a company, or an amendment to a previous filing, indicating their passive investment intent. They provide transparency regarding significant ownership stakes, which can influence market perception of a stock's institutional backing.
Comparison to Industry Standards
- NA
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| NA | NA | NA | NA | NA |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| NA | NA | NA | NA |
Legal Proceedings
- NA
Related Party Transactions
- NA
Stakeholder Impact
- Shareholders of Entrada Therapeutics gain transparency regarding a significant institutional investor's stake.
- The filing indicates a passive investment intent by Janus Henderson, which generally suggests stability rather than an activist stance.
Next Steps
- NA
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Execution date of Power of Attorney by Janus Henderson Group plc. |
| 2025-06-30 | Date of event which requires filing of this statement. |
| 2025-08-14 | Signature date of the Schedule 13G Amendment No. 2. |
Keywords
Entrada Therapeutics, Janus Henderson, Schedule 13G, beneficial ownership, common stock, investment adviser, holding company, SEC filing, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.